|
|
- oncology,
- central nervous system,
- cardio-vascular diseases,
- immunology applied to the prevention of infectious diseases and anti-cancer therapy,
- dermatology.
With the support of a highly active policy of partnerships with public and private institutions, Pierre Fabre Laboratories focus their efforts on the R&D of original compounds of natural, synthetic or biological origin. R&D in Oncology is focused on areas of major medical interest, that is on types of cancer with a high incidence and mortality such as specific solid tumours (breast, lung, colon, ovary, bladder or ENT cancers) or, in onco-haematology, lymphomas, myelomas or bone marrow transplants.
Research in oncology is Pierre Fabre’s area of excellence. It represents the major therapeutic field of the Group and has been supported for several years by a very significant effort. Around 50% of R&D investments in the Group’s medical product branch are currently devoted to oncology. Pierre Fabre has thus become the second company in France in terms of investment in oncological research.